It has been gradually established that the vast majority of human tumors are extraordinarily 18 heterogeneous at a genetic level. To accurately recapitulate this complexity, it is now evident that 19 in vivo animal models of cancers will require to recreate not just a handful of simple genetic 20 alterations, but possibly dozens and increasingly intricate. Here, we have combined the 21 RCAS/TVA system with the CRISPR/Cas9 genome editing tools for precise modeling of human 22 tumors. We show that somatic deletion in neural stem cells (NSCs) of a variety of known tumor 23 suppressor genes (Trp53, Cdkn2a and Pten), in combination with the expression of an oncogene 24 driver, leads to high-grade glioma formation. Moreover, by simultaneous delivery of pairs of 25 guide RNAs (gRNAs) we generated different gene fusions, either by chromosomal deletion 26 (Bcan-Ntrk1) or by chromosomal translocation (Myb-Qk), and we show that they have 27 transforming potential in vitro and in vivo. Lastly, using homology-directed-repair (HDR), we 28 also produced tumors carrying the Braf V600E mutation, frequently identified in a variety of 29 subtypes of gliomas. In summary, we have developed an extremely powerful and versatile mouse 30 model for in vivo somatic genome editing, that will elicit the generation of more accurate cancer 31 models particularly appropriate for pre-clinical testing. 32 33 34 provide the chance to introduce defined genetic lesions into specific cell types, leading to the 57 development of more accurate tumor models. 58
Introduction 35
A decade of studies has underlined the complexity of the genetic events that characterize 36 the genomic landscapes of common forms of human cancer 1 . While a few cancer genes are 37 mutated at high frequencies (>20%), the greatest number of cancer genes in most patients appear 38 at intermediate frequencies (2-20%) or lower 2 . Strikingly, the functional significance of the vast 39 majority of these alterations still remains elusive. A current high priority in cancer research is to 40 functionally validate candidate genetic alterations to distinguish those that are significant for 41 cancer progression and treatment response. In order to do so, it is essential to develop flexible 42 genetically engineered mouse models that can speed up the functional identification of cancer 43 driver genes among the large number of passenger alterations 3 . 44
The growing level of sophistication of the genome engineering technologies has made it 45 possible to target almost any candidate gene in the in vivo setting. The CRISPR (Clustered 46 Regularly Interspaced Short Palindromic repeats) -Cas (CRISPR-associated), the most powerful 47 genome editing system so far, has revolutionized research in many fields, including cancer 48 animal modelling, by allowing precise manipulation of the genome of individual cells. Its 49 applications span from the inactivation of tumor suppressor genes, to the generation of somatic 50 point mutations and more complex genomic rearrangements such as gene fusion events. 51
A possibly significant limitation of CRISPR-based in vivo somatic genome editing is the 52 requirement to concurrently deliver the RNA guides and the Cas9 enzyme to the specific tissue 53 of interest. To deal with this issue, various groups recently generated transgenic mice expressing 54 Cas9 in a Cre-or tetracycline-dependent manner 4-6 . The combination of somatic genome 55 editing with the vast collection of currently available genetically engineered mouse models will 56
Here we describe a series of new mouse models that combine the genome editing 65 capability of the CRISPR/Cas9 system with the somatic gene delivery of the RCAS/TVA 66 approach to generate precision tumor modeling. To prove the efficacy of such a powerful system, 67
we produced a number of in vivo and ex vivo models of glioma with tailored genetic alterations. 68
The gliomas are a large group of brain tumors and within gliomas the glioblastoma 69 (GBM) is the most frequent form of the disease and overall the most common and lethal primary 70 central nervous system (CNS) tumor in adults. A series of large-scale genomic analysis has 71 underlined the complexity of the genetic events that characterize the glioma genome. However, 72 so far, we have been able to study only a minority of these genetic alterations due to the lack of 73 appropriate tumor models. 74
We took advantage of the previously developed Rosa26-LSL-Cas9 (LSL-Cas9) knockin 75 mouse strain 4 and combined it with the Nestin-tv-a (Ntv-a) and the GFAP-tv-a (Gtv-a) 76 transgenic mice that express the TVA receptor under the control of the rat nestin and human 77 GFAP promoter, respectively 8, 9 . Moreover, we have further crossed those strains with either the 78 Nestin-Cre (Nes-Cre) or hGFAP-Cre transgenic lines 10,11 , to allow for Cas9 expression in neural 79 stem/progenitor cells and in astrocytes, or with a mouse strain carrying a tamoxifen-activated 80 recombinase, hUBC-CreERT2 12 , for ubiquitous and inducible Cas9 expression. 81
Through in vivo delivery of RCAS plasmids that carry guided RNAs (gRNAs) for a series 82 of tumor suppressor genes known to be frequently deleted in GBM (Trp53, Cdkn2a and Pten), in 83 combination with the expression of the Platelet Derived Growth Factor Subunit B (PDGFB), we 84
show that we can efficiently generate high-grade gliomas in mice that express both Cas9 and 85 TVA in the Nestin or GFAP positive cells. Moreover, by simultaneous ex vivo transduction into 86 neural stem cells (NSCs) of RCAS plasmids expressing pairs of gRNAs we generated either 87 chromosomal deletion (Bcan-Ntrk1 gene fusion) or chromosomal translocation (Myb-Qk gene 88 fusion) and we show that they lead to glioma formation when transplanted in 89 immunocompromised mice. We further generated Braf mutant gliomas by inducing a homology-90 directed repair-mediated BRAF V600E mutation. 91
Lastly, by ex vivo treatment of some of these tumor models we demonstrate their utility 92 for pre-clinical testing of targeted therapies. 93
In conclusion, combining the RCAS/TVA and CRISPR/Cas9 models we have developed 94 an extremely powerful mouse model for in vivo somatic genome editing, that allows targeting 95 specific cell types with definite genetic alterations to generate precision tumor models. 96
97
Results 98
Generation of CNS Cas9-expressing mouse strains 99
To test the possibility of somatic genome editing by combining the RCAS/TVA and 100 CRISPR/Cas9 models, we generated a series of mouse strains that allowed the TVA and Cas9 101 expression in specific cell types in the brain. 102
Nestin is an intermediate filament protein (IFP) that is predominantly expressed in the 103 central nervous system stem/ progenitor cells during embryonic development, but also in 104 muscles and other tissues. In adult organism, its expression in the brain is mainly restricted to the 105 neural stem cell compartment of the subventricular zone (SVZ). After differentiation, nestin is 106 downregulated and replaced by tissue-specific IFPs. The glial fibrillary acidic protein (GFAP) is 107 an IFP that is expressed by numerous cell types of the CNS including astrocytes and ependymal 108 cells. Nestin-tv-a (Ntv-a) and GFAP-tv-a (Gtv-a) transgenic mice that express the TVA receptor 109 under the control of the rat nestin and human GFAP promoter, have been widely used for 110 modeling brain tumorigenesis 8, 9, 13 . 111
The Rosa26-LSL-Cas9 knockin mice (LSL-Cas9) have a floxed-STOP cassette 112 precluding expression of the downstream bicistronic sequences (Cas9-P2A-EGFP) and it was 113 generated to overcome the delivery challenges of the Cas9 enzyme to specific tissues of interest 114 4 . We crossed these mice with the Ntv-a and Gtv-a transgenic mice to obtain the Ntv-a; LSL-115
Cas9 and Gtv-a; LSL-Cas9. Although RCAS-Cre expressing plasmids have been previously used 116 in combination with different TVA expressing mice to allow tissue specific deletion of a variety 117 of floxed alleles 13-15 , to ensure a robust recombination in the CNS of the floxed-STOP cassette 118 in the Ntv-a; LSL-Cas9 and Gtv-a; LSL-Cas9 we further crossed these mice with either the 119 Nestin-Cre (Nes-Cre) or hGFAP-Cre transgenic lines 10,11 . The resulting Ntv-a; Nes-Cre; LSL-120
Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 mice presented no abnormalities in development and 121 size ( Supplementary Fig. 1a ), were fertile and had normal litter sizes. 122
The Nestin-Cre is expressed quite early during development, beginning at E9.5, while the 123 hGFAP-Cre appears to be expressed around E12.5-E13.5 10,11 . Both strains lead to widespread expression of the Cas9-P2A-EGFP throughout the brain of adult mice and pups ( Fig. 1a-b and 125 Supplementary Fig. 1b ). Also of note it is the co-localization of NESTIN and GFAP with EGFP 126 in the area of the sub-ventricular zone ( Fig. 1a-b To explore whether the newly engineered RCAS/tv-a/Cas9 strains where suitable for in 131 vivo genome editing, we first generated a series of RCAS plasmids that would allow the 132 expression of gRNAs. For this purpose, we sub-cloned into the RCAS vector a cassette carrying 133 a human U6 promoter (hU6), followed by a PGK promoter that drove the expression of a 134 puromycin resistance gene (Puro) linked to a blue fluorescent protein (BFP) via a self-cleavable 135 T2A peptide (hU6-gRNA-PGK-Puro-T2A-BFP) ( Fig. 2a ). We then cloned different previously 136 described gRNAs targeting tumors suppressor genes (TSGs) frequently altered in high-grade 137 gliomas: Trp53, Cdkn2a and Pten. All the RCAS plasmids generated for our studies were 138 constructed using intermediate vectors compatible with the Gateway cloning system and the 139 previously described RCAS-destination vector 16 (see Methods for details). To test the knockout 140 efficiency of the RCAS-gRNA plasmids, we derived NSCs from Ntv-a; LSL-Cas9 and infected 141 them with a Cre-expressing plasmid to induce Cas9 expression. In parallel we also generated, by 142 retroviral infection, NIH3T3 mouse fibroblasts expressing both TVA and the Cas9 genes. We 143 then infected both cell lines with multiple rounds of infections using the various RCAS-gRNA 144 plasmids. After either drug-selection (for the NSCs TVA-Cas9) or fluorescent activated cell 145 sorting (FACS) (for the BFP in the NIH-3T3 TVA-Cas9) we verified the deletion of Trp53, 146
Cdkn2a and Pten by western blot analysis. Since NIH-3T3 cells are Cdkn2a null, we tested the 147 Cdkn2a gRNAs only in the NSCs. As shown in figure 2b, we observed efficient deletion of all 148 those genes in both cellular systems. 149
We then tested the ability of the Trp53, Cdkn2a and Pten gRNAs to cooperate with 150 PDGFB to induce high-grade gliomas (GBM) when injected into the Ntv-a; Nes-Cre; LSL-Cas9 151 and Gtv-a; hGFAP-Cre; LSL-Cas9 mice. RCAS-PDGFB intracranial injection into Ntv-a and 152
Gtv-a pups has been previously shown to be sufficient to induce gliomas with variable 153 penetrance (from 40% to 75%), but only a small fraction of the injected mice (25%) presented 154 high-grade tumor features, such as pseudopalisades necrosis and microvascular proliferation [17] [18] [19] . Moreover, RCAS-PDGFB injection into Ntv-a and Gtv-a adult mice resulted in very low 156 tumor penetrance (approximately 15-20%) and long latency (over 100 days) 13 . Co-injections 157 RCAS-PDGFB and RCAS-TSG-gRNA (either one of Trp53, Cdkn2a or Pten gRNAs) into Ntv-158 a; Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 pups resulted in a shortened tumor 159 latency and increased total tumor incidence as compared to the co-injections of RCAS-PDGFB 160 and RCAS-gRNA non-targeting control (Ctrl) ( Fig. 2c and Supplementary Fig. 2 ). Most 161 importantly, the vast majority (80-100%) of the RCAS-PDGFB/RCAS-TSG-gRNA injected 162 mice showed histological features of high-grade gliomas ( Fig. 2c-d ). We also generated RCAS 163 plasmids expressing the gRNA and the PDGFB in the same constructs (hU6-gRNA-PGK-Puro-164 T2A-PDGFB) ( Fig. 2a ). When injected into Ntv-a; Nes-Cre; LSL-Cas9 pups, the RCAS-Cdkn2a-165 gRNA-PDGFB bicistronic vector was able to induce high-grade tumor formation with full 166 penetrance and very short latency (approximately 40 days) ( Fig. 2c and Supplementary Fig. 2 
). 167
Analogously to what was previously reported for the RCAS-PDGFB, injection in adult 168 mice showed a considerably reduced tumor incidence. Actually, in our 120 days' experimental 169 timeframe, we didn't observe any tumors in the mice co-injected with the RCAS-PDGFB and 170 RCAS-gRNA non-targeting control neither in the Ntv-a; Nes-Cre; LSL-Cas9 nor in the Gtv-a; 171 hGFAP-Cre; LSL-Cas9. However, similarly to the injections in the pups, the injection of RCAS-172 PDGFB/RCAS-TSG-gRNA in adult mice lead to increased tumor incidence, with the majority of 173 the tumor presenting high-grade characteristics ( Fig. 2c and Supplementary Fig. 2 ). 174 Immunohistochemical (IHC) analysis of paraffin-embedded tissue showed loss of Trp53, 175
Cdkn2a and Pten expression in the tumors injected with the corresponding RCAS-TSG-gRNA 176 plasmid ( Fig. 2d ). 177
In summary, these data demonstrate that RCAS-gRNA constructs can induce deletion of 178 the gene of interest in an in vivo setting and they could be used to efficiently target virtually any 179 tumor suppressor gene. Supplementary Fig. 3c ). Mice did not show any signs of inflammation and 210 splenomegaly was not observed. Circulating levels of T-cells, B-cells, granulocytes and 211 monocytes were determined by flow cytometry in the blood and spleen. While there were no 212 significant differences neither in T cells (CD3 + CD4 + ) nor B cells (CD3 -B220 + ), there was a trend 213 towards decreased circulating Gr-1 positive neutrophils in the blood of the Ntv-a; LSL-Cas9; 214 hUBC-CreERT2 +/T tamoxifen-treated mice, which could signify inefficient production of these 215 cells in the bone marrow ( Fig. 3a ). Despite this reduction, we did not detect significant 216 differences in neither the number nor the percentage of granulocytes in whole blood cell counts 217 that is highly expressed in the brain, while NTRK1, that codes for the TrkA kinase, is almost 249 undetectable in the adult brain ( Supplementary Fig. 4b ). The mouse homologues, Bcan and 250 Ntrk1, located on Chr3, have a similar gene structure and expression pattern to their human 251 counterparts ( Supplementary Fig. 4a-b ). Hence, we argued that the Bcan-Ntrk1 fusion would be 252 an appropriate genomic alteration to be studied with the RCAS/tv-a/Cas9 system. 253
In order to generate the Bcan-Ntrk1 gene fusion we designed gRNAs in the introns 13 254 and 10 of Bcan and Ntrk1, respectively (Fig. 4a ). The pair of gRNAs was subsequently cloned 255 into an RCAS plasmid containing both a hU6 and mU6 promoters (hU6-gRNA-mU6-gRNA-256 PGK-Puro-T2A-BFP) (RCAS-gRNA-pair) ( Fig. 4b, top infiltration in the normal brain parenchyma ( Fig. 4e and Supplementary Fig. 4d-e ). Bcan-Ntrk1-induced tumors showed elevated percentage of Ki67 positive cells, were positive for OLIG2 and 280 NESTIN, negative for the neuronal marker NeuN and, besides the small percentage of astrocytes 281 trapped inside the tumor, GFAP positive cells were almost exclusively detected at the 282 normal/tumor border ( Fig. 4d ). Moreover, IHC staining evidenced high level of expression of 283
Ntrk1 as compared to a PDGFB-induced tumor ( Supplementary Fig. 4f ). 284
We further confirmed by genomic PCR and FISH analysis the presence of the Ntrk1 gene fusion on cells isolated from the tumor-bearing mice, propagated in vitro as 286 tumorspheres ( Supplementary Fig. 4g-h) . Strikingly, these tumorspheres expressed very high 287 levels of Ntrk1 as compared to both the NSCs control or to the Bcan-Ntrk1 NSCs prior 288 intracranial injection ( Supplementary Fig. 4i ). These data would suggest that in vivo, from the 289 mixed population of the NSCs infected with the Bcan-Ntrk1 gRNAs, those cells that carried the 290 gene rearrangement were positively selected. 291
There has been a lot of interest lately in targeting NTRK gene fusions across multiple 292 tumor types 31 . Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing 293 clinical trials in a variety of cancers. To confirm that the Bcan-Ntrk1 tumors we generated were 294 dependent on TrkA activity, we treated in vitro with Entrectinib the Bcan-Ntrk1 tumorspheres. 295
As shown in figure 4f, the Bcan-Ntrk1 tumorspheres were exquisitely sensitive to Trk inhibition, 296 while no effect was observed on the control p53-null TVA-Cas9 NSCs. Entrectinib led to a 297 significant reduction of tumor cells growth associated with an increase of the number of 298 apoptotic cells, detected as sub-G1 population in a propidium iodide staining ( Fig. 4f-g) . 299
Overall these data indicate that the RCAS/TVA-CRISPR/Cas9 system is a very powerful 300 model to study the role of gene fusions in tumorigenesis and as possible therapeutic targets. MYB encodes for a transcription factor that is a key regulator of hematopoietic cell 311 proliferation and deregulated MYB activity has been observed in variety of human cancers. QKI 312 is a tumor suppressor gene that encodes for a RNA-binding protein, QUAKING, that plays a role 313 in the development of the CNS, among other organs. Several MYB-QKI gene fusions have been 314 described in angiocentric gliomas, all of them involved the same QKI 3' region (exon 5 to 8) 315 fused to different MYB exons (1-9, 1-11 or 1-15). Here, we focused on the most frequent MYB 316 (exon1-9) -QKI (exon 5 to 8) fusion event. 317
To generate the mouse Myb (exon1-9) -Qk (exon 5 to 8) fusion, we designed gRNAs in 318 the intron 4 for Myb and 9 for Qk (Fig. 5a ), and we cloned them into the RCAS-gRNA-pair. 319
Genomic PCR and sequencing from the NIH-3T3 TVA-Cas9 (data not shown) and also from 320 p53-null TVA-Cas9 NSCs infected with the RCAS-Qk-gRNA-Myb-gRNA, confirmed the 321 generation of the Myb-Qk fusion (Fig. 5b ). By RT-PCR we also observed the expression of the 322
Myb-Qk transcript (Fig. 5c ). 323
In human and mouse normal adult brain, Myb mRNA expression is almost undetectable 324 ( Supplementary Fig. 5b ). The MYB-QKI fusion has been shown to functionally activate the MYB 325 promoter and to possibly contribute to an autoregulatory feedback loop 32 . Indeed, when we 326 measured Myb expression in cells expressing the Myb-Qk fusion we observed an increase of Myb 327 mRNA as compared to control cells (Fig. 5d ). We also observed increased mRNA levels of a 328 series of genes (Erbb2, Cdk6 and Slc9a31) that have been shown to be upregulated by the MYB-329 QKI fusion 32 (Fig. 5d ). 330
We then tested their transforming potential in vitro by plating the cells in soft-agar, and 331 we observed that the p53-null NSCs expressing the Myb-Qk fusion, but not the p53-null NSCs 332 infected with the Ctrl gRNA cells, were able to form colonies. 333 334
Modeling BRAF V600E mutation by homology directed repair (HDR) 335
One of the known applications of the CRISPR/Cas9 system is to induce point mutations 336 through Homologous Recombination (HR). Delivery of a gRNA with either double-stranded 337 DNA (dsDNA) or single-stranded DNA (ssDNA) repair templates, containing a desired modified 338 sequence together with variable length upstream and downstream homology arms, has been used 339 to recreate oncogenic driver mutations 4 .
Activating mutations in the BRAF kinase gene (V600E) have been identified in various 341 types of pediatric gliomas (Pilocytic astrocytomas (<10%), pleomorphic xanthoastrocytomas 342 (WHO grades II and III; 50%-65% cases), gangliogliomas (20%-75% cases)) and also adult 343 high-grade gliomas (5%) 33 . 344
To model a missense gain-of-function Braf mutation we used the strategy previously 345 and also a second point mutation D624N ( Supplementary Fig. 6a ). This latter mutation, although 357 undesired, is a conservative mutation from an aspartate to an asparagine residue and it's not 358 expected to have any functional consequence on BRAF activity. 359
When transplanted intracranially into NOD/SCID mice, the p53-null Braf V637E NSCs 360 induce tumor formation in 100% of the injected mice (6/6), with an average survival of 66 ± 11.5 361 days. Histopathological examination of the tumors evidenced a number of features characteristic 362 of high-grade gliomas: nuclear atypia, high number of mitotic figures and necrotic areas ( Fig. 6b  363 and Supplementary Fig. 6b ). Moreover, we observed clusters of tumor cells infiltrating the 364 normal brain parenchyma, with the vast majority of these cells surrounding tumor vessels 365 ( Supplementary Fig. 6b ), resembling the vascular co-option observed both in primary and 366 metastatic brain tumors. It is also to note the presence of some giant cells ( Supplementary Fig.  367 6c) and areas of the tumors with epithelioid morphology ( Supplementary Fig. 6d ). 368
Immunohistochemical analysis of the BRAF mutant tumors revealed high percentage of 369 Ki67 positive cells, positivity for both OLIG2 and NESTIN and elevated MAPK kinase activity, 370 as evidenced by pERK IHC (Fig. 6b ). Additionally, we were able to confirm the expression of the BRAF V637E mutation using an antibody specifically designed to recognize the human 372 BRAF V600E mutant. 373
To validate that the BRAF mutant tumors were dependent on an active BRAF signaling 374 pathway, we isolated tumorspheres from two of those tumors and we treated them in vitro with 375 Dabrafenib, a specific BRAF inhibitor that is currently in clinical trials for BRAF V600E mutant 376 melanomas. Both tumorspheres lines carried the Braf V637E mutation as confirmed by PCR and 377
Sanger sequencing ( Supplementary Fig. 6e ). As shown in figure 6d , Dabrafenib treatment 378 induced growth reduction in both Braf V637E tumors, but not in p53-null NSCs. Moreover, western 379 blot analysis showed a reduction of MAPK kinase signaling pathway after exposure to 380 Dabrafenib in Braf V637E tumor cells but not in control cells (Fig. 6e) . 381
In summary, we have presented a platform that will be useful to study not only the role of 382 tumor suppressor genes and genomic rearrangements but also of potential oncogenic mutations. For the TSGs we selected Trp53, Cdkn2a and Pten, since they were previously shown to 413 cooperate with PDGFB overexpression to induce high-grade gliomas 13,18 . Indeed, co-injection of 414 gRNAs targeting those genes led to the formation of GBMs with high frequency. These data 415 would suggest that combining the expression of specific oncogene drivers with gRNAs for a 416 TSG of interest would quickly provide information on its contribution to the tumorigenesis 417 process. Moreover, by using the hUBC-CreERT2 +/T or other Cre-inducible strains it will be 418 possible to exploit the RCAS/TVA-CRISPR/Cas9 system not only to study tumor initiation, but 419 also tumor progression and maintenance. 420
Due to the quite recent advancement in the CRISPR/Cas9 technology, very few mouse 421 models have been previously developed to study brain tumorigenesis [38] [39] [40] . By in utero 422 electroporation (IUE) of the forebrain of mouse embryos using plasmids encoding Cas9 in 423 combination with gRNAs targeting Nf1, Trp53 and Pten, Zuckerman and Chen were able to 424 induce highly aggressive tumors that had histopatological features of human GBMs. More 425 recently, Cook and colleagues have used adenoviral (Ad) vectors to express Cas9 and to generate 426 the BCAN-NTRK1 rearrangement in the brain of adult mice 40 . 427
In our opinion there are at least two key issues with the use of IUE and Ad for glioma 428 CRISPR/Cas9 modeling: timing of the gRNA delivery and lack of specificity of the targeted 429 cells. Electroporation is normally performed at E14.5 or E15.5 and genetic alterations at this 430 gestational stage might not be necessarily reflecting the biology of gliomas in the adult. The 431 second issue is that the expression of the Cas9 enzyme from a constitutive promoter, as it has 432 been used in both IUE and Ad studies, does not allow genome editing in a cell-type-specific manner hence not restricting the genetic alteration to the putative cells of origin of gliomas. This 434 latter point is particularly relevant for proper cancer modeling, since it has been shown that the 435 same driver mutations can lead to phenotypically and molecularly diverse glioma subtypes from 436 different pools of adult CNS progenitor cells 41, 42 . 437
The CRISPR/Cas9 system has been previously used to model genomic rearrangements 438 both in human and mouse cells [43] [44] [45] We have observed that the NTRK1 gene fusions lead to overexpression of the chimeric 446 NTRK1 transcripts in human glioma patients and in our mouse model ( Supplementary Fig. 4c  447 and 4i). Most likely, the very pronounced levels of TrkA kinase activity achieved by the high 448 levels of the chimeric NTRK1 transcripts are responsible for the oncogenic activity of those 449 fusions. Indeed, we observed that the Bcan-Ntrk1 tumors were finely sensitive to the pan-Trk 450 inhibitor Entrectinib. 451
The MYB-QKI rearrangement has been shown to drive tumorigenesis through a tripartite 452 mechanism: MYB activation by truncation, aberrant MYB-QKI expression and hemizygous loss 453 of the tumor suppressor QKI 32 . Using the RCAS/TVA-CRISPR/Cas9 system we successfully 454 generated the Myb-Qk gene fusion in mouse cells and indeed we observed an increased Myb 455 activation, as shown by upregulation of some Myb-regulated genes (Erbb2, Cdk6 and Slc9a31) 456 ( Fig. 5d ). Although it is conceivable that loss of the Qk gene is contributing to the tumorigenic 457 potential of the cells carrying the Myb-Qk gene fusion, further work will be needed to clarify it. 458
Despite that the generation of point mutations with the CRISPR/Cas9 system might 459 represent one of the most powerful feature of this genome editing technology, it is also the most 460 challenging and very few cancer models have been developed with it 4,47-49 . Here we generated 461 the first CRISPR/Cas9 model for the BRAF V600E mutation. To generate the pDONR-gRNA that expressed also the PDGFB-HA, we performed a 494 PCR using the Platinum Pfx Kit and the primers pDONR-Fw and Rv for the backbone and PDGFB-Fw and Rv for the insert (Supplementary Table1 ). The two fragments were then 496 assembled using the Gibson Assembly Master Mix (New England Biolabs, Cat. E2611L). To 497 obtain the final plasmid, the BbsI restriction site in the PDGFB sequence (pDONR-sgRNA-498 PDGFB position 2822) was removed by site-directed mutagenesis using the primers PDGFB_ 499
BbsI_mut-Fw and Rv. 500
The pDONR-gRNA plasmids were recombined into the RCAS-Y-DV using the Gateway 501 LR Clonase II Enzyme mix (Invitrogen, Cat. 11791100), following the manufacturer's 502 instructions. All the constructs were verified by Sanger-sequencing. 503
The gRNA sequences targeting Cdkn2a, Pten and Tp53 were previously described 38, 55, 56 . Viruses, other than RCAS, were generated in Gp2-293 using calcium-phosphate 543 precipitate transfection: lentiviruses (pKLV-U6gRNA-PGKpuro2ABFP and lentiCas9-Blast) 544
were produced by co-transfection with 2nd generation packaging vectors (pMD2G and psPAX2) 545 and retroviruses (pMSCVhygro-CRE) with VSVg packaging vector. High-titer virus was 546 collected at 36 and 60hr following transfection and used to infect cells in presence of 7μg/ml 547 polybrene (Sigma-Aldrich, Cat. H9268-5G) for 12hr. Transduced cells were selected after 48hr 548 from the last infection with Blasticidin (3μg/ml) (Gibco, Cat. A11139-03) or Hygromycin 549 (300μg/ml) (Sigma-Aldrich, Cat. H3274-25MG). 550
Entrectinib (RXDX-101) and Dabrafenib (GSK2118436) were purchased from 551 Selleckchem (Cat. S7998 and S2807, respectively). 552
NSCs and Tumorspheres Preparation 553
For the derivation of mouse NSCs and tumor neurospheres, the tissue was enzymatically 554 digested with 5 ml of papain digestion solution (0.94 mg/ml papain (Worthington, Cat. 555 LS003119), 0.48mM EDTA, 0.18mg/ml N-acetyl-L-cysteine (Sigma-Aldrich, Cat. A9165-5G) in Earl's Balanced Salt Solution (EBSS) (Gibco, Cat. 14155-08)) and incubated at 37°C for 8min. 557
After digestion, the enzyme was inactivated by the addition of 2ml of 0.71mg/ml ovomucoid 558 (Worthington, Cat. LS003087) and 0.06mg/ml DNaseI (Sigma-Aldrich, Cat. 10104159001) 559 diluted in Mouse Neurocult NSC basal medium (Stem Cell Technologies, Cat. 05700) without 560 growth factors. The cell suspension was then passed through a 40μm mesh filter to remove 561 undigested tissue, washed first with PBS and then with 3 ml of ACK lysing buffer (Gibco, Cat. 562 A1049201). Single cells suspension was then centrifuged at a low speed and resuspended in 563
Mouse NeuroCult proliferation kit (Stem Cell Technologies, Cat. 05702), supplemented with 564 10ng/ml recombinant human EGF (Gibco, Cat. PHG0313), 20ng/ml basic-FGF (Sigma-Aldrich, 565
Cat. F0291-25UG), and 1mg/ml Heparin (Stem Cell Technologies, Cat. 07980). 566 567
Free Floating ImmunoFluorescence (FF-IF) 568
Adult (4-6 weeks) and pups (1 day) brains were fixed with PFA 4% (Electron 569
Microscopy Sciences, Cat. 15713) and then incubated with sucrose 15% and 30%. Each step was 570 done overnight at 4°C. Brains were then sectioned by using a sliding microtome with freezing 571 stage (Fisher) . Sections of 80 μm were blocked in Goat Serum 10%, BSA 2%, Triton 0.25% and 572 mouse on mouse blocking reagent (Vectors Laboratories, Cat. BMK-2202) in PBS for 2hr at 573 room temperature (RT). Primary antibodies were incubated overnight at 4°C in the blocking 574 solution and the following day for 30 min at RT as detailed: GFAP (Millipore, MAB360, 1:500), 575 NESTIN (BD Pharmingen, #556309, 1:100) and EGFP (Aves Labs, GFP-1010, 1:1000). Slices 576 were then washed in PBS-Triton 0.25% and incubated with the secondary antibody for 2hr. 577 Secondary antibodies were from Invitrogen (Alexa-Fluor anti-chicken 488 , anti-rabbit 555 , anti-578 mouse 555 ). After extensive washing in PBS-Triton 0.25%, nuclei were stained with DAPI for 579 3 min at RT. Sections were mounted with ProLong Gold Antifade reagent (Invitrogen, Cat. 580 P10144). 581
Brain mapping was performed with a TCS SP5 confocal microscope (Leica 582 Microsystems) equipped with Leica HCS-A and custom made iMSRC software 57 . Final images 583 were acquired with a 20x 0.7 N.A. dry objective. The regions of interest definition were done on 584 mosaics of the full brain sections acquired with a 10 x 0.4 N.A. dry objective. 585
Immunoblotting 586 1:100), pan-TRK (Cell Signaling Technology, #92991, 1:100) were performed using an 618 automated immunostaining platform (Ventana discovery XT, Roche). BRAF V600E 619 immunostaining was performed on a Leica Bond-III stainer (Leica Biosystem, Newcastle, UK) 620 with a 1:100 dilution of anti-BRAF V600E (VE1) mouse monoclonal primary antibody (Spring 621 Bioscience, Pleasanton, CA). 622
Blood Counts and Flow Cytometry 623
For the analysis of the Cas9-induced immune response, 4 weeks old Ntv-a; LSL-Cas9; 624 hUBC-CreERT2 mice were fed ad libitum with tamoxifen containing diet for the duration of the 625 experiment ( Supplementary Fig. 3a) . 626
Complete blood counts were carried out using the Abacus Junior Vet (Diatron). Cells 627 were isolated from spleen and brain by mechanical disruption. Red Blood Cells were lysed using 628 the red blood cell lysis buffer (Sigma-Aldrich). All cells were stained with CD45-PerCP 629 Samples were acquired in an LSR Fortessa (BD, San Jose CA) equipped with 355nm, 488nm, 633 561nm and 640nm lines. We used pulse processing to exclude cell aggregates and DAPI to 634 exclude dead cells. All data were analyzed using FlowJo 9.9.4 (Treestar, Oregon). 635
Cell Proliferation, Soft-Agar Assay and Cell Cycle Analysis 636
NSCs and tumorspheres cells were seeded in 96-well culture plates (4,000 per well) in 637 quintuplicate and treated for 96hr. At the end of the incubation period, survival of cells was 638 determined by the MTT assay. Briefly, MTT was added to each well and samples were incubated 639 for 4h before lysing in formazan dissolving solution. Colorimetric intensity was quantified using 640 an ELISA reader at 590 nm. Values were obtained after subtraction of matched blanks (medium 641 only). The OD values of DMSO controls were taken as 100% and values for drug treatment are 642 expressed as % of control. 643
The soft-agar growth assay was performed by seeding cells in triplicates at 300,000 644 cells/well in NSCs culture medium containing 0.4% Noble agar (Sigma-Aldrich, Cat. A5431). 645
Cells were plated on top of a layer of NSCs culture medium containing 0.65% Nobel agar.
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Mouse Strains and Husbandry 709
Nestin-tv-a and GFAP-tv-a 8,9 were generously provided by Eric Holland. Rosa26-LSL-710
Cas9 knockin mouse strain 4 was purchased from The Jackson laboratory (Cat. 024857). Nestin-711 Braf V637E tumorspheres exposed for 96h to increasing doses of Dabrafenib. (e) Western blot 979 analysis using the specified antibodies on p53-null TVA-Cas9 NSCs and Braf V637E tumorspheres 980 grown for 24h in absence of growth factors and then treated with Dabrafenib (200nM) for the 981 indicated time.
